Biological Matrices Versus Synthetic Meshes (BIOSYM)
Primary Purpose
Breast Cancer
Status
Not yet recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
One-stage immediate breast reconstruction
Sponsored by

About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring breast reconstruction, mesh, acellular dermal matrix, synthetic mesh, breast cancer, patient reported outcome
Eligibility Criteria
Inclusion Criteria:
Female age ≥ 18 Women undergoing mastectomy and immediate one-stage mesh assisted implant breast reconstruction as standard treatment
Exclusion Criteria:
Revision reconstruction surgery Delayed reconstruction surgery
Sites / Locations
- University Hospitals of Derby and Burton NHS Foundation Trust
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Biological Matrix
Synthetic Mesh
Arm Description
Participants will undergo immediate breast reconstruction using biological matrix and implant
Participants will undergo immediate breast reconstruction using synthetic mesh and implant
Outcomes
Primary Outcome Measures
Clinician acceptance
Proportion of eligible women offered the trial
Patient acceptance
Proportion of women offered the trial who participate in the trial
Recruitment rate
Number of patient recruited per year per site
Compliance with allocated intervention
Number of patients not complying with randomisation allocation
Secondary Outcome Measures
Full Information
NCT ID
NCT05449691
First Posted
July 4, 2022
Last Updated
October 5, 2023
Sponsor
University Hospitals of Derby and Burton NHS Foundation Trust
1. Study Identification
Unique Protocol Identification Number
NCT05449691
Brief Title
Biological Matrices Versus Synthetic Meshes
Acronym
BIOSYM
Official Title
BIOSYM - A Feasibility Randomised Controlled Trial Comparing Biological Matrices With Synthetic Meshes in Women Undergoing One Stage Implant Based Breast Reconstruction
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
November 1, 2023 (Anticipated)
Primary Completion Date
April 30, 2026 (Anticipated)
Study Completion Date
April 30, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospitals of Derby and Burton NHS Foundation Trust
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this feasibility study, 60 women undergoing reconstruction will be randomly allocated to receive biological or synthetic mesh and followed for 6 months. The findings will tell us if patients and surgeons are comfortable with not being able to choose which mesh is used for the operation. In the larger surgical study, the investigators plan to measure patients' satisfaction with the reconstruction, patients' quality of life, complications from the operation and costs over 5 years.
Detailed Description
Immediate breast reconstruction in women undergoing removal of the whole breast for cancer or risk reduction is most commonly done using breast implants. Surgeons often use a sheet of mesh to cover the implant as standard treatment. It acts like an internal bra and supports the implant and re-creates a natural looking breast.
Natural(biological) or man-made (synthetic) meshes are used routinely in the NHS. Biological ones are made from animal tissue (pig, cow) that have been made safe to use in people and are costly. Synthetic meshes are made from net-like fabric and cost less. The choice about which mesh to use depends on surgeons' personal experience and how much money the hospital has for these operations. The two meshes may have different acceptability issues for patients because of their personal values, religious beliefs, ethnic background or views on animal welfare.
A large UK review of breast reconstruction with implants gathered information up to 3 months after surgery on the use and outcomes of the two meshes. This suggests that both may be equally safe in the short-term. However, this information can be improved by comparing the meshes side-by-side and looking at how safe they are long-term. This is important as some side-effects only appear later after surgery. Clinicians do not know how outcomes impact on patients' health and well-being.
The best proof would come from a randomised surgical study, where a computer allocates patients to receive either the biological or synthetic mesh. Investigators will measure how patients feel, how their health is, and record if they have any side-effects from the reconstructive surgery. This type of study would tell us how good each mesh is and if they are safe long-term.
Before starting such a study, investigators will run a smaller one that will help us understand if patients and surgeons would be comfortable taking part.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
breast reconstruction, mesh, acellular dermal matrix, synthetic mesh, breast cancer, patient reported outcome
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Masking Description
Single blind masking
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Biological Matrix
Arm Type
Active Comparator
Arm Description
Participants will undergo immediate breast reconstruction using biological matrix and implant
Arm Title
Synthetic Mesh
Arm Type
Experimental
Arm Description
Participants will undergo immediate breast reconstruction using synthetic mesh and implant
Intervention Type
Procedure
Intervention Name(s)
One-stage immediate breast reconstruction
Intervention Description
One-stage mesh assisted implant breast reconstruction
Primary Outcome Measure Information:
Title
Clinician acceptance
Description
Proportion of eligible women offered the trial
Time Frame
2 years
Title
Patient acceptance
Description
Proportion of women offered the trial who participate in the trial
Time Frame
2 years
Title
Recruitment rate
Description
Number of patient recruited per year per site
Time Frame
2 years
Title
Compliance with allocated intervention
Description
Number of patients not complying with randomisation allocation
Time Frame
2 years
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female age ≥ 18 Women undergoing mastectomy and immediate one-stage mesh assisted implant breast reconstruction as standard treatment
Exclusion Criteria:
Revision reconstruction surgery Delayed reconstruction surgery
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Amit Goyal, MS, MD, FRCS
Phone
01332786958
Email
amit.goyal@nhs.net
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amit Goyal, MS, MD, FRCS
Organizational Affiliation
University Hospitals of Derby and Burton NHS Foundation Trust
Official's Role
Study Chair
Facility Information:
Facility Name
University Hospitals of Derby and Burton NHS Foundation Trust
City
Derby
ZIP/Postal Code
DE22 3NE
Country
United Kingdom
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amit Goyal, MS, MD, FRCS
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Biological Matrices Versus Synthetic Meshes
We'll reach out to this number within 24 hrs